Oxytocin attenuates feelings of hostility depending on emotional context and individuals' characteristics

Scientific Reports (Impact Factor: 5.58). 04/2012; 2:384. DOI: 10.1038/srep00384
Source: PubMed

ABSTRACT In humans, oxytocin (OT) enhances prosocial behaviour. However, it is still unclear how the prosocial effects of OT are modulated by emotional features and/or individuals' characteristics. In a placebo-controlled design, we tested 20 healthy male volunteers to investigate these behavioural and neurophysiological modulations using magnetoencephalography. As an index of the individuals' characteristics, we used the empathy quotient (EQ), the autism spectrum quotient (AQ), and the systemising quotient (SQ). Only during the perception of another person's angry face was a higher SQ a significant predictor of OT-induced prosocial change, both in the behavioural and neurophysiological indicators. In addition, a lower EQ was only a significant predictor of OT-induced prosocial changes in the neurophysiological indicators during the perception of angry faces. Both on the behavioural and the neurophysiological level, the effects of OT were specific for anger and correlated with a higher SQ.

Download full-text


Available from: Tsunehisa Tsubokawa, Dec 25, 2013
1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Studies have argued that empathy to the pain of out-group members is largely diminished by "in-group empathy bias". Investigating the mechanism underlying the emotional reactions of Jewish Israeli participants toward the pain experienced by Palestinians in the context of the Israeli-Palestinian conflict affords a natural experiment that allows us to examine the role of neurohormones in emotion sensitivity across conflicting social groups. In a double-blind placebo-controlled within-subject crossover design, Israeli Jewish participants were asked to report their empathy to the pain of in-group (Jewish), neutral out-group (European), and adversary out-group (Palestinian) members. Oxytocin remarkably increased empathy to the pain of Palestinians, attenuating the effect of in-group empathy bias observed under the placebo condition. This effect, we argue, is driven by the general role of oxytocin in increasing the salience of social agents which, in turn, may interfere with processes pertaining to derogation of out-group members during intractable conflicts.
    Psychoneuroendocrinology 09/2013; 38(12). DOI:10.1016/j.psyneuen.2013.09.015 · 5.59 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The nine amino acid peptide oxytocin (OXT) has been directly associated with different types of behavioral reactions. The formation and maintenance of social relationships in youth and middle age are important components of human mental health. A deficit in healthy behavioral formation leads to social isolation and limitation of well-being. Mice are social animals and are therefore useful for investigating the neurobiological mechanisms of cognitive process control, including the development of social relationships and social skills. Studies in mice may broaden our understanding of the human condition. The multifunctional protein CD38/ADP-ribosyl cyclase is highly expressed in the brain, plays an important role in central OXT release, and regulates social memory. In this review article, we discuss the mechanisms of social behavior affected by the dysregulation of brain OXT function as a consequence of a lack of CD38. OXT bound to OXT receptors initiates autoregulatory positive feedback of OXT release in the hypothalamus and posterior pituitary. OXT bio-behavioral positive feedback is usually implicated in female reproductive systems, but can also be observed in social behavior. Exogenous stimuli (OXT treatment in vitro, OXT intravenous or intraventricular administration, and nasal OXT delivery) initiate activation of OXT neurons via PKC-CD38/ADP-ribosyl cyclase cascades and result in the modulation of social behavior in humans and mice. Based on these findings, we reviewed the functions of OXT and its properties with respect to the development of therapies for human social behavior impairments in psychological diseases. In addition, preliminary studies of continuous nasal OXT administration on subjects with autism spectrum disorders are described.
    Frontiers in Neuroscience 01/2012; 6:182. DOI:10.3389/fnins.2012.00182
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Concerns regarding a drought in psychopharmacology have risen from many quarters. From one perspective, the wellspring of bedrock medications for anxiety disorders, depression, and schizophrenia was serendipitously discovered over 30 year ago, the swell of pharmaceutical investment in drug discovery has receded, and the pipeline's flow of medications with unique mechanisms of action (i.e., glutamatergic agents, CRF antagonists) has slowed to a trickle. Might oxytocin (OT)-based therapeutics be an oasis? Though a large basic science literature and a slowly increasing number of studies in human diseases support this hope, the bulk of extant OT studies in humans are single-dose studies on normals, and do not directly relate to improvements in human brain-based diseases. Instead, these studies have left us with a field pregnant with therapeutic possibilities, but barren of definitive treatments. In this clinically oriented review, we discuss the extant OT literature with an eye toward helping OT deliver on its promise as a therapeutic agent. To this end, we identify 10 key questions that we believe future OT research should address. From this overview, several conclusions are clear: (1) the OT system represents an extremely promising target for novel CNS drug development; (2) there is a pressing need for rigorous, randomized controlled clinical trials targeting actual patients; and (3) in order to inform the design and execution of these vital trials, we need further translational studies addressing the questions posed in this review. Looking forward, we extend a cautious hope that the next decade of OT research will birth OT-targeted treatments that can truly deliver on this system's therapeutic potential.
    Frontiers in Neuroscience 01/2013; 7:35. DOI:10.3389/fnins.2013.00035